BTIG Raises Glaukos and AtriCure Targets, Keeps Buy Ratings
BTIG lifted Glaukos’s target to $205 from $202 and AtriCure’s to $63 from $55, while maintaining Buy ratings on both stocks.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reported that BTIG raised its price target for Glaukos to $205.00 a share from $202.00. The firm maintained its Buy rating on the stock. The update was published at 10:09 GMT on October 12, 2026.
At 10:04 GMT the same day, BTIG also lifted its target for AtriCure to $63.00 a share from $55.00, while keeping its Buy rating. Benzinga published the analyst actions, linking to its rating pages for Glaukos and AtriCure.
why it matters
Changes in analyst targets and ratings can affect how investors assess a stock. These updates concern two healthcare companies and represent revisions to BTIG’s valuation views.
instruments
sources
- Glaukos Price Target Raised to $205.00/Share From $202.00 by BTIG — Dow Jones Newswires, 12 October 2026 at 10:09 UTC
- AtriCure Price Target Raised to $63.00/Share From $55.00 by BTIG — Dow Jones Newswires, 12 October 2026 at 10:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗